Business Context and Reporting Period
Company: Sanofi-Synthelabo (now Sanofi)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter 2003 (Ended March 31, 2003)
Release Date: April 24, 2003
Accounting Basis: French GAAP
Key Financial Metrics
Consolidated Sales: 1,959 million euros (Q1 2003) vs. 1,727 million euros (Q1 2002).
- Growth (Comparable Basis): +13.4% (Constant structure and exchange rates).
- Growth (Reported Basis): +5.6%.
- Currency Impact: Unfavorable impact of 7.3 percentage points, primarily due to the weakening US dollar.
- Structural Impact: Unfavorable impact of 0.5 percentage points.
Top 10 Products: Generated 1,285 million euros (65.6% of total sales), up 30.4% on a comparable basis.
Developed Sales: 2,397 million euros, up 9.8% on a comparable basis.
Share Buyback: As of March 31, 2003, the company held 28 million shares acquired for 1.5 billion euros (3.8% of share capital).
Profitability, Cash Flow, Debt, and Liquidity: The filing text does not provide specific values for net income, operating cash flow, total debt, or liquidity ratios. It only confirms the outlook for earnings per share (EPS).
Material Changes vs. Prior Period
- United States: Reported sales increased 11.1% to 471 million euros; comparable growth was 31.6%. This was driven by Eloxatin (100 million euros) and Ambien (285 million euros, +22.8% comparable). Sales of Primacor nearly disappeared (2 million euros vs. 49 million euros in Q1 2002) due to generic competition.
- Europe: Sales reached 1,155 million euros, up 8.5% on a comparable basis, outperforming market growth.
- Rest of World: Reported sales fell 7.8% to 333 million euros due to currency weakness and a change in consolidation ratio for Sanofi-Synthelabo-Fujisawa (Taiwan). Comparable growth was +9.2%.
- Product Performance:
- Eloxatin: +225.8% comparable growth.
- Plavix: +25.5% comparable growth (39.3% excluding sales to partner Bristol-Myers Squibb).
- Aprovel: +35.6% comparable growth.
- Stilnox/Ambien: +21.2% comparable growth.
Outlook, Risks, and Management Commentary
2003 Guidance: Management confirmed the February 18, 2003 forecasts for sales and EPS growth.
- Sales Growth: Expected to be similar to 2002 levels on a comparable basis.
- EPS Growth: Expected to increase close to 20% (before exceptional items and goodwill amortization) assuming an exchange rate of 1 euro = 1 dollar. Sensitivity is 1% EPS growth for every 3 cent movement in the dollar.
Operational Highlights & Risks:
- Plavix Invoicing: US invoiced sales decreased 14% on a comparable basis despite a 27.2% rise in prescriptions. This was attributed to wholesaler destocking, an unfavorable comparison basis, and reduced incentives by Bristol-Myers Squibb. Management expects full-year invoiced sales to align with prescription demand.
- Regulatory: ANDROMEDA study for dronedarone discontinued due to safety concerns in high-risk heart failure patients; pivotal trials for atrial fibrillation (EURIDIS/ADONIS) continued. FDA approved Eligard 30 mg and granted priority review for Arixtra in hip fracture surgery.
- Partner Restatement: Confirmed no need to modify Sanofi's financial statements following Bristol-Myers Squibb's restatement of accounts for 1999-2002.
- Forward-Looking Risks: Expansion in the US, R&D success, intellectual property protection, and healthcare reimbursement/pricing reforms.
Investor Verification Checklist
- Verify the reconciliation of "Developed Sales" vs. "Consolidated Sales" to understand the full market impact of alliance products (Plavix, Aprovel).
- Monitor the trend of Plavix wholesaler inventory levels in the US to confirm if invoiced sales will recover to match prescription growth.
- Assess the impact of the discontinued ANDROMEDA study on the dronedarone pipeline and future R&D costs.
- Track the exchange rate sensitivity of the 20% EPS guidance, given the significant currency headwinds in Q1.
- Confirm the timeline for the new Arixtra indication approval and its potential revenue contribution.